Drugs & Therapy Perspectives

, Volume 21, Issue 2, pp 1–5 | Cite as

Extended-release tolterodine is an effective and convenient option in the treatment of overactive bladder

Drugs and Profile Reports


  1. 1.
    Keam SJ, Perry CM. Management of overactive bladder: defining the role of extended-release tolterodine. Dis Manage Health Outcomes 2004; 12(2): 124–42Google Scholar
  2. 2.
    Hashim H, Abrams P. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs 2004; 64(15): 1643–56PubMedCrossRefGoogle Scholar
  3. 3.
    Garely AD, Burrows L. Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults. Drug Saf 2004; 27(13): 1043–57PubMedCrossRefGoogle Scholar
  4. 4.
    Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61: 37–49PubMedCrossRefGoogle Scholar
  5. 5.
    British National Formulary. No. 48. London: The Pharmaceutical Press, 2004 SepGoogle Scholar
  6. 6.
    Van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001; 57(3): 414–21PubMedCrossRefGoogle Scholar
  7. 7.
    Freeman R, Hill S, Millard R, et al. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstet Gynecol 2003 Sep; 102(3): 605–11PubMedCrossRefGoogle Scholar
  8. 8.
    Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for over-active bladder in older versus younger patients. J Am Geriatr Soc 2002; 50(5): 799–807PubMedCrossRefGoogle Scholar
  9. 9.
    Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol 2002; 41(6): 588–95PubMedCrossRefGoogle Scholar
  10. 10.
    Kelleher CJ, Kreder KJ, Pleil AM, et al. Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002; 8(19 Suppl.): S616–30PubMedGoogle Scholar
  11. 11.
    Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA Trial. Mayo Clin Proc 2003 Jun; 78: 687–95PubMedCrossRefGoogle Scholar
  12. 12.
    Homma Y, Paick JS, Lee G, et al. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int 2003 Nov; 92(7): 741–7PubMedCrossRefGoogle Scholar
  13. 13.
    Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003 Aug; 62(2): 237–42PubMedCrossRefGoogle Scholar
  14. 14.
    Kelleher CJ, Reese PR, Pleil AM, et al. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002; 8(19 Suppl.): S608–15PubMedGoogle Scholar
  15. 15.
    Kurth H, Pieters R, Sloesen B, et al. An economic model of unstable bladder in Belgium [abstract no. PRK4]. Value Health 2002 Nov–Dec; 5(6): 582CrossRefGoogle Scholar
  16. 16.
    Bentkover J, Bachleda M, Kulseng-Hansen S, et al. An economic model of overactive bladder in Norway [abstract no. PUK4]. Value Health 2002 May–Jun; 5(3): 275CrossRefGoogle Scholar
  17. 17.
    Noe L, Becker R, Williamson T, et al. A pharmacoeconomic model comparing two long-acting treatments for overactive bladder. J Manage Care Pharm 2002 Sep–Oct; 8(5): 343–52Google Scholar
  18. 18.
    Yu YF, Yu AP, Ahn J, et al. Comparison of direct health-care cost, hospitalization and medication persistence between extended release forms of tolterodine and oxybutynin in overactive bladder/ urinary incontinence patients [abstract no. PRK1]. Value Health 2003 May–Jun; 6(3): 285CrossRefGoogle Scholar
  19. 19.
    Pharmacia Limited. Detrusitol XL 4mg SPC from the eMC [online]. Available from URL: [Accessed 2004 Jan 20]
  20. 20.
    Pharmacia & Upjohn Company. Detrol LA: tolterodine tartrate extended release capsules [online]. Available from URL: [Accessed 2003 Nov 24]

Copyright information

© Adis Data Information BV 2005

Personalised recommendations